Truist raises Texas Instruments stock price target on demand recovery By Investing.com

Texas Instruments received multiple analyst target raises after strong first-quarter results and second-quarter guidance, with Truist lifting its target to $278 from $225 while maintaining a Hold rating. Truist also increased its 2027 EPS estimate to $8.68 from $7.50, citing demand broadening beyond AI and data centers into industrial applications; other firms cited targets of $280-$325. The stock was trading at $275.80, and the company’s 14.89% trailing 12-month revenue growth and 22-year dividend growth streak support the positive fundamental backdrop.

Analysis

TXN is being repriced less on the reported beat than on the market’s willingness to pay for a higher-quality cyclical recovery. The key second-order effect is that broadening demand from AI/datacenter into industrials reduces the risk of a single-end-market air pocket, but it also caps upside because analog recovery is now becoming visible to everyone, not just a handful of channel checks. When consensus shifts from “depressed cycle” to “normalized cycle,” multiple expansion tends to stall before earnings growth does.

The relative winner here is not necessarily TXN; it is the lower-quality analog/industrial suppliers that still have margin catch-up ahead of them. If Truist is right that suppliers with less recovered margins will show stronger operating leverage, then TXN may actually be the benchmark that others use to justify higher targets across the group, while the best total-return trade may sit in names with more torque to utilization and pricing rather than the highest current quality.

Near term, the main risk is that the current upgrade wave becomes a valuation event rather than an earnings event. Over the next 1-3 months, any sign that industrial demand is merely restocking rather than end-demand would pressure the multiple, especially after a strong multi-quarter run. Over 6-12 months, the bear case is that TXN’s cash-flow durability remains intact but the stock underperforms if earnings revisions flatten and investors rotate toward faster-margin-recovery names.

Contrarian view: the market may be over-anchoring on the ‘broadening recovery’ narrative and underestimating how much of the upside is already in the stock. A 32x forward multiple implies very little room for execution slippage, so the better asymmetry may be to fade TXN strength relative to peers with lower starting multiples and more operating leverage.

Key Decisions for Investors

• Hold TXN rather than add aggressively; use strength to trim into any move above the revised target zone because the risk/reward is now skewed toward multiple compression if revisions slow over the next 1-2 quarters.
• Pair trade: long a lower-quality analog/industrial name with recovering margins versus short TXN for a 3-6 month window; the thesis is that TXN has less earnings torque left while the laggards still have operating leverage.
• For investors who must own TXN, fund it with a short in a semis basket that has more cyclical beta and weaker balance sheets; this reduces downside if the sector rerates lower on valuation but keeps exposure to the industrial recovery.
• Consider buying medium-dated TXN puts or put spreads into any post-upgrade squeeze if implied volatility is still reasonable; best use is as a hedge against a 10-15% de-rating rather than a crash.
• Watch for channel and distributor commentary over the next 4-8 weeks; if industrial demand proves to be inventory rebuild rather than true end-demand, reduce TXN exposure quickly and rotate toward names with stronger revenue surprise potential.